Press Releases

bioMérieux to present at the 43rd Annual J.P. Morgan HealthCare Conference

Marcy l’Étoile, France, January 13, 2025 – bioMérieux, a world leader in the field in vitro diagnostics, today announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, USA, from January 13 to 16, 2025.

BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance. This innovative polymerase-chain reaction (PCR) testing solution offers fast and accurate pathogen identification in patients with unexplained fever, helping to optimize treatment overall.

Financial Information

Third-Quarter 2024 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2024: Consolidated sales amounted to €2,871 million, representing an organic growth of +10.3% at constant exchange rates and scope of consolidation.

Business & Solutions

bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration

bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® VITAMIN B12 TOTAL, an automated quantitative test for use on the VIDAS® immunoassay instruments, for the measurement of total Vitamin B12 concentration in human serum or plasma.

Financial Information

First-Half 2024 Results

Marcy l’Etoile (France), September 5th, 2024 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4th under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2024.

Business & Solutions

bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).